Evotec Reports Q1 2026 Results: Transformation Underway

Evotec SE has announced its financial results for the first quarter of 2026, confirming full-year guidance amidst ongoing strategic transformation. Group revenues reached €156.6 million, with an adjusted EBITDA of -€21.9 million, affected by one-off impacts and foreign exchange challenges. Key partnerships with Almirall and the Gates Foundation are progressing, with promising developments in preclinical drug candidates.

The company has launched the implementation phase of its Horizon transformation strategy, focusing on operational efficiency and cost reduction. Evotec anticipates cumulative savings of about €75 million by 2027. Leadership changes see Claire Hinshelwood as CFO and Dr. Ingrid Müller as COO, aiming to bolster the operational model while ensuring financial compliance.